Ori CAR 004
Alternative Names: Ori®-CAR-004Latest Information Update: 23 Jun 2022
Price :
$50 *
At a glance
- Originator OriCell Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 10 Jun 2022 Ori CAR 004 is available for licensing as of 10 Jun 2022. https://www.oricell.com/en/
- 10 Jun 2022 Preclinical trials in Multiple myeloma in China (Parenteral) (OriCell Therapeutics pipeline, June 2022)
- 10 Jun 2022 Oricell Therapeutics intends to file IND application for Multiple myeloma (Oricell Therapeutics pipeline, June 2022)